Citations

Clear

3030 citation(s) found for "Susan, M".

Abstract A06: Association of environmental risk factors, family history, and polygenic risk scores with chronic lymphocytic leukemia
Kleinstern, Geffen , Robinson, Dennis H., Call, Tim G., Liebow, Mark , Sanjosé, Sílvia de , Benavente, Yolanda , Robinson, Dennis, Call, Timothy G., Cerhan, James R. , Slager, Susan L.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 9, 2019 | Volume: 26 | Issue: 5_Supplement | Pages: A06-A06

10.1158/1538-7755.carisk16-a06 Get It

Abstract This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR03) of the Conference Proceedings. Citation Format: Geffen Kleinstern, Dennis Robinson, Tim G. Call, Mark Liebow, Silvia de Sanjosé, Yolanda Benavente, James R. Cerhan, Susan L. Slager. Association of environmental risk factors, family history, and polygenic risk scores with chronic lymphocytic leukemia. [abstract]. In: Proceedings of the AACR Special Conference: Improving Cancer Risk Prediction for Prevention and Early Detection; Nov 16-19, 2016; Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2017;26(5 Suppl):Abstract nr A06.
Abstract A44: Coffee consumption and colorectal cancer risk by molecularly defined subtypes in a prospective cohort study of older women
Singh, Siddharth, Tillmans, Lori S. , Wang, Alice , Weisenberger, Daniel J. , Laird, Peter W., Inoue‐Choi, Maki , Mariani, Andrea , Lynch, Charles F. , Anderson, Kristin E. , French, Amy J. , Smyrk, Thomas C. , Thibodeau, Stephen N. , Vierkant, Robert A. , Haile, Robert W. , Harnack, Lisa , Potter, John D. , Slager, Susan L. , Cerhan, James R. , Limburg, Paul J.

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: A44-A44

10.1158/1940-6215.prev-13-a44 Get It

Abstract Background: Different molecules within coffee may be pro-carcinogenic, while others may have anti-oxidant and anti-neoplastic effects. Hence, it can be hypothesized that coffee may have differing risk associations with specific colorectal cancer (CRC) subtypes. The aim of this study was to evaluate associations between coffee consumption and incident CRC overall, by anatomic subsite, and by molecularly defined tumor subtypes, in the population-based Iowa Women's Health Study (IWHS). Methods: IWHS participants, ages 55-69 years, provided dietary intake estimates using self-reported food frequency questionnaires at baseline (1986). From 35,216 women included the final analysis, 1298 developed CRC (673 with proximal CRC, 597 with distal CRC) through December 31, 2002 (end of the IWHS molecular epidemiology project study period). Archived, paraffin-embedded tissue specimens for 732 representative CRC cases were collected and analyzed to determine if coffee consumption (none or <1 cup/month, <1 cup/week, 1 cup/day, 2-3 cups/day and ≥4 cups/day) was associated with microsatellite instability (MSI-L/MSS or MSI-H), CpG island methylator phenotype (CIMP-negative or CIMP-positive), BRAF mutation status (BRAF-wildtype or BRAF-mutated), KRAS mutation status (KRAS-wildtype and KRAS-mutated), p53 protein expression level (p53 absent, low or high) and estrogen receptor β protein expression level (ERβ absent, low or high). Multivariable Cox regression models were fit to estimate relative risks (RR) and 95% confidence intervals (CI) with adjustment for age, smoking, alcohol use, diabetes, body mass index and waist-hip ratio, physical activity, estrogen use, dietary intake of fat, calcium, vitamin E, sucrose, red meat and methionine. P-values were not adjusted for multiple testing. Results: There was no significant difference in the risk of overall (RR, 1.05; 95% CI, 0.85-1.29; Ptrend=0.50), proximal (RR, 0.91; 95% CI, 0.68-1.21; Ptrend=0.57) or distal CRC (RR, 1.18; 95% CI, 0.86-1.64; Ptrend=0.19) in women who consumed ≥4 cups of coffee/day (caffeinated or decaffeinated), as compared to non-consumers. By CRC molecular subtypes for these same two exposure groups, women with ≥4 cups of coffee/day were more likely to develop ERβ-low CRC (RR, 2.98; 95% CI, 1.04-8.51; Ptrend=0.06), though no significant associations were observed for caffeinated or decaffeinated coffee specifically. In contrast, women who consumed ≥4 cups of decaffeinated coffee/day were less likely to develop MSI-L/MSS (RR, 0.57; 95% CI, 0.36-0.92; Ptrend=0.04) and BRAF-WT (RR, 0.69; 95% CI, 0.44-1.06; Ptrend=0.06) CRCs than non-consumers. Women who consumed ≥4 cups of caffeinated coffee/day were also less likely to develop p53-low CRCs (RR, 0.53; 95% CI, 0.24-1.15; Ptrend=0.02). Null associations were observed between decaffeinated coffee consumption and risk of CIMP-, KRAS- and p53- defined CRC subtypes, as well as between caffeinated coffee consumption and risk of MSI-, BRAF-, CIMP- or KRAS-defined CRC subtypes. Conclusion: In this prospective cohort study of older women, though coffee consumption was not associated with risk of overall or site-specific CRC, unique associations were observed with molecularly defined CRC subtypes, supporting a need for further investigation of the potential pro- and anti-carcinogenic effects of coffee constituents on biologic targets involved in colorectal carcinogenesis. Citation Format: Siddharth Singh, Robert Vierkant, Lori Tillmans, Alice Wang, Daniel Weisenberger, Peter Laird, Maki Inoue-Choi, Andrea Mariani, Charles Lynch, Kristin Anderson, Amy French, Robert Haile, Lisa Harnack, John Potter, Susan Slager, Thomas Smyrk, Stephen Thibodeau, James Cerhan, Paul Limburg. Coffee consumption and colorectal cancer risk by molecularly defined subtypes in a prospective cohort study of older women. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr A44.
Sex Matters in Health and Disease: a review of biological sex differences with an emphasis on glioma
Whitmire, Paula , Doyle, Tatum E, Ippolito, Joseph E. , Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Fitzpatrick, Susan M., Swanson, Kristin R. , Swanson, Kristin R , Ippolito, Joseph E , Massey, Susan Christine , Anderson, Alexander R.A. , Wilson, Melissa A. , McCarthy, Margaret M. , Rubin, Joshua B

Mayo Clinic

No container title available | May 9, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27716v1 Get It

Humans are sexually dimorphic, with sex being the most persistent difference among humans over the course of our evolutionary history. Beyond the visible sex differences that can be considered true dimorphisms, there are also sex differences at the molecular and cellular scales. The role of these biological sex differences for human health, while being increasingly recognized, have long been underappreciated and underexplored. Frequently, these differences are only recognized in sex–specific diseases, such as genitourinary diseases and cancers. However, given the evidence for sex differences in the most basic aspects of human biology, including metabolism, cellular composition, and immune activity, these differences could have consequences for the etiology and pathophysiology of a majority of diseases. It is thus essential to consider the extent to which these differences may influence the various mechanisms underlying disease processes, response to treatment, and the maintenance of health in order to better improve patient outcomes. Here we review the evidence for a broad array of biological sex differences in humans and discuss how they may relate to observed sex differences in various diseases, with an emphasis on cancer, specifically glioblastoma. We further propose that mathematical approaches can be useful for exploring the extent to which sex differences affect disease outcomes and accounting for those in the development of therapeutic strategies.
Efficacy of proton therapy in children with high‐risk and locally recurrent neuroblastoma
Bagley, Alexander F. , Grosshans, David R. , Philip, Nancy V., McAleer, Mary Frances , McGovern, Susan L. , Lassen–Ramshad, Yasmin , Mahajan, Anita , Paulino, Arnold C. , Foster, Jennifer , Paulino, Arnold C , Bagley, Alexander F

Mayo Clinic

Pediatric Blood & Cancer | May 3, 2019 | Volume: 66 | Issue: 8 | Pages: No page available

10.1002/pbc.27786 | PMID 31050179 Get It

Abstract Purpose Proton therapy is currently used in the management of pediatric tumors to decrease late toxicities. However, one of the criticisms of proton therapy is the limited data regarding efficacy on disease control. The purpose of this study was to examine local and distant control rates after proton therapy for neuroblastoma. Methods and materials Eighteen patients with high‐risk ( n = 16) and locally recurrent neuroblastoma ( n = 2) were treated with curative intent and received proton therapy to the primary site and up to three post‐induction MIBG‐avid metastatic sites. Primary sites ( n = 18) were treated to 21–36 Gy (relative biological effectiveness [RBE]), and metastatic sites ( n = 16) were treated to 21–24 Gy (RBE). Local control and survival rates were calculated using the Kaplan–Meier method. Results With a median follow‐up of 60.2 months, two‐ and five‐year local control rates at the irradiated primary site were 94% and 87%, respectively. No failures at irradiated distant metastatic sites were observed. The five‐year progression‐free survival (PFS) was 64%, and the five‐year overall survival (OS) was 94%. The extent of surgical resection was not associated with local control, PFS, or OS. No radiation‐related nephropathy or hepatopathy was reported. Conclusions Excellent local control was achieved using proton therapy to the primary and post‐induction MIBG‐positive distant sites. The predominant site of failure is progression in post‐induction non‐MIBG‐avid distant sites. Although proton therapy provides high rates of local control with acceptable toxicity for neuroblastoma, further advances in systemic therapy are needed for the improved control of systemic disease.
Laryngotracheal Microbiota in Adult Laryngotracheal Stenosis
Tang, Sharon , Carlos, Camila , Skarlupka, Joseph H. , Gowda, Madhu, Yin, Linda X. , Motz, Kevin , Suen, Garret , Suen, Garret , Motz, Kevin M , Yin, Linda X , Hillel, Alexander T. , Gowda, Madhu, Currie, Cameron R. , Thibeault, Susan L.

Mayo Clinic

mSphere | May 1, 2019 | Volume: 4 | Issue: 3 | Pages: No page available

10.1128/mspheredirect.00211-19 | PMID 31043518 Get It

The laryngotracheal region resides at the intersection between the heavily studied nasal cavity and lungs; however, examination of the microbiome in chronic inflammatory conditions of the subglottis and trachea remains scarce. To date, studies have focused on the microbiota of the vocal folds, or the glottis, for laryngeal carcinoma, as well as healthy larynges, benign vocal fold lesions, and larynges exposed to smoking and refluxate. In this study, we seek to examine the structure and composition of the microbial community in adult laryngotracheal stenosis of various etiologies. Due to the heterogeneity among the underlying pathogenesis mechanisms and clinical outcomes seen in laryngotracheal stenosis disease, we hypothesized that different microbial profiles will be detected among various stenosis etiology types. Understanding differences in the microbiota for subglottic stenosis subtypes may shed light upon etiology-specific biomarker identification and offer novel insights into management approaches for this debilitating disease.
A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Jones, Robin L. , Chawla, Sant P. , Attia, Steven , Schöffski, Patrick , Gelderblom, Hans , Cesne, Axel Le, Patel, Shreyaskumar , Wagner, Andrew J. , Heyburn, John, Weil, Susan C., Viele, Kert , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Gelderblom, Hans , Chmielowski, Bartosz , Tine, Brian A. Van , Trent, Jonathan C. , Chugh, Rashmi , Wang, Wenquan

Mayo Clinic

Cancer | April 30, 2019 | Volume: 125 | Issue: 14 | Pages: 2445-2454

10.1002/cncr.32084 | PMID 31034598 Get It

Background Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM‐1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. Methods Part 1 was an open‐label, dose‐finding, safety lead‐in: 4, 6, or 8 mg/kg with gemcitabine and docetaxel (G/D; 900 mg/m 2 gemcitabine on days 1 and 8 and 75 mg/m 2 docetaxel on day 8). In part 2, patients were randomized in a double‐blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts. Results In part 2 with 209 patients, no significant difference in progression‐free survival between ontuxizumab plus G/D (4.3 months; 95% confidence interval [CI], 2.7‐6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6‐8.3 months) was observed ( P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77‐1.49). Similarly, there was no significant difference in median overall survival between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2‐21.1 months) and 21.1 months for the placebo plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82‐1.82). No significant differences between the treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally well tolerated. Conclusions Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft‐tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone.
Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry
Crotti, Lia , Spazzolini, Carla , Tester, David J. , Ghidoni, Alice , Baruteau, Alban‐Elouen , Beckmann, Britt Maria , Behr, Elijah R. , Bennett, Jeffrey S. , Bezzina, Connie R. , Bhuiyan, Zahurul A. , Çeliker, Alpay, Cerrone, Marina , Etheridge, Susan P. , Fatah, Meena , García‐Pavía, Pablo , Hamilton, Robert M. , Al‐Hassnan, Zuhair N. , Horie, Minoru , Jiménez‐Jáimez, Juan , Kanter, Ronald J. , Kaski, Juan Pablo , Kotta, Maria‐Christina , Lahrouchi, Najim , Makita, Naomasa , Norrish, Gabrielle , Odland, Hans Henrik , Ohno, Seiko , Papagiannis, John , Parati, Gianfranco , Sekarski, Nicole , Tveten, Kristian , Vatta, Matteo , Wilde, Arthur A.M. , Wojciak, Julianne, Ackerman, Michael J. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , Kotta, Maria-Christina , Baruteau, Alban-Elouen , Garcia-Pavia, Pablo , Cerrone, Marina , Hamilton, Robert , Kaski, Juan P , Odland, Hans H , Sekarski, Nicole , Bezzina, Connie R , Spazzolini, Carla , Çeliker, Alpay , Dagradi, Federica , Ferrari, Gaetano Maria De , Al-Ghamdi, Saleh, Ohno, Seiko , Webster, Gregory , George, Alfred L. , Schwartz, Peter J.

Mayo Clinic

European Heart Journal | April 29, 2019 | Volume: 40 | Issue: 35 | Pages: 2964-2975

10.1093/eurheartj/ehz311 | PMID 31170290 Get It

Abstract Aims Calmodulinopathies are rare life-threatening arrhythmia syndromes which affect mostly young individuals and are, caused by mutations in any of the three genes (CALM 1–3) that encode identical calmodulin proteins. We established the International Calmodulinopathy Registry (ICalmR) to understand the natural history, clinical features, and response to therapy of patients with a CALM-mediated arrhythmia syndrome. Methods and results A dedicated Case Report File was created to collect demographic, clinical, and genetic information. ICalmR has enrolled 74 subjects, with a variant in the CALM1 (n = 36), CALM2 (n = 23), or CALM3 (n = 15) genes. Sixty-four (86.5%) were symptomatic and the 10-year cumulative mortality was 27%. The two prevalent phenotypes are long QT syndrome (LQTS; CALM-LQTS, n = 36, 49%) and catecholaminergic polymorphic ventricular tachycardia (CPVT; CALM-CPVT, n = 21, 28%). CALM-LQTS patients have extremely prolonged QTc intervals (594 ± 73 ms), high prevalence (78%) of life-threatening arrhythmias with median age at onset of 1.5 years [interquartile range (IQR) 0.1–5.5 years] and poor response to therapies. Most electrocardiograms (ECGs) show late onset peaked T waves. All CALM-CPVT patients were symptomatic with median age of onset of 6.0 years (IQR 3.0–8.5 years). Basal ECG frequently shows prominent U waves. Other CALM-related phenotypes are idiopathic ventricular fibrillation (IVF, n = 7), sudden unexplained death (SUD, n = 4), overlapping features of CPVT/LQTS (n = 3), and predominant neurological phenotype (n = 1). Cardiac structural abnormalities and neurological features were present in 18 and 13 patients, respectively. Conclusion Calmodulinopathies are largely characterized by adrenergically-induced life-threatening arrhythmias. Available therapies are disquietingly insufficient, especially in CALM-LQTS. Combination therapy with drugs, sympathectomy, and devices should be considered.
Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice
Hampel, Paul J. , Ding, Wei , Call, Timothy G. , Rabe, Kari G. , Muchtar, Eli , Leis, José F., Chanan‐Khan, Asher , Koehler, Amber B. , Fonder, Amie , Schwager, Susan M., Shanafelt, Tait D. , Kenderian, Saad S. , Muchtar, E , Chanan-Khan, Asher A., Fonder, Amie L, Chaffee, Kari G. , Ding, Wei , Shanafelt, Tait D , Hampel, Paul J , Witzig, Thomas E. , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

Leukemia & Lymphoma | April 24, 2019 | Volume: 60 | Issue: 11 | Pages: 2712-2719

10.1080/10428194.2019.1602268 | PMID 31014142 Get It

A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.
Chawla, Sant P. , Schöffski, Patrick , Attia, Steven , Tine, Brian Andrew Van, Patel, Shreyaskumar , Wagner, Andrew J. , Viele, James Kert, Cesne, Axel Le , Sankhala, Kamalesh K. , Falcone, Julianne, Schweizer, Charles, Weil, Susan C., Blay, Jean‐Yves , Jones, Robin L. , Gelderblom, Hans , Chmielowski, Bartosz , Trent, Jonathan C. , Chugh, Rashmi , Tinoco, Gabriel , Maki, Robert G.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS10577-TPS10577

10.1200/jco.2015.33.15_suppl.tps10577 Get It